MHY-1685 is primarily investigated for its potential in biomedical research, particularly in the study of cellular aging and age-related diseases. It is known to inhibit mTOR (mechanistic target of rapamycin), a key regulator of cell growth, proliferation, and survival. By targeting this pathway, it is explored for its role in extending lifespan and improving healthspan in model organisms. Researchers are also examining its potential in cancer therapy, as mTOR signaling is often dysregulated in various cancers. Additionally, MHY-1685 is studied for its neuroprotective effects, with potential applications in neurodegenerative disorders like Alzheimer's disease. Its ability to modulate autophagy further broadens its scope in understanding and treating conditions linked to cellular dysfunction.